Dr Aviral Singh
MD PGDipCard MSc FAfNM, Nuclear Medicine Physician
Theranostics may help to provide a comparatively safer, targeted, and individualised option for the management of cancer patients.
Languages spoken
English, Hindi, German, Russian
Overview
Clinical interests in prostate cancer, neuroendocrine neoplasms, and other difficult-to-treat cancers.
Dr Aviral Singh is a Specialist Physician in Nuclear Medicine currently working as the Clinical Research and Development Manager in the GenesisCare Australia Theranostics team. He has relocated from Germany, where he was working as a Consultant Physician in Nuclear Medicine & Theranostics and Clinical Research Physician at the ENETS Center of Excellence, Zentralklinik Bad Berka.
Following graduation in medicine from Ukraine, he acquired clinical training in nuclear medicine, intensive care and internal medicine from Germany, Australia and United Kingdom in English, German and Russian languages.
Aviral gained the degree of M.Sc. in Nuclear Medicine from King’s College London, University of London, UK in 2015, and is pursuing PhD from Maastricht University, Netherlands.
In 2016 Aviral was recognised for his scientific poster in clinical oncology, by the Society of Nuclear Medicine and Molecular Imaging 2016, San Diego, USA. In 2017, he was a keynote guest speaker on the topic of neuroendocrine tumour therapies at ‘György Hevesy’ Hungarian Society of Nuclear Medicine and enlisted in The Leading Physicians of the World of 2017 edition of The International Association of HealthCare Professionals. In 2018 he was invited faculty at the European Society of Medical Oncology (ESMO) and also invited faculty – European Neuroendocrine Tumor Society (ENETS), 9th Postgraduate course, Barcelona, Spain in 2019.
He has deep clinical and research interests in Theranostics for the management of neuroendocrine neoplasms and prostate cancer.
Aviral has published peer-reviewed scientific papers in medical journals and abstracts presented at various international medical societies globally. His ResearchGate H-Index is 21. He has participated as a Clinical Investigator in multicentre clinical trials, such as the NETTER-1 and COMPETE.
With a keen interest in medical education, Aviral has been invited as Guest Faculty and Invited Lecturer by a number of international medical societies.
Since 2018 Aviral is the elected Treasurer and Member of the Executive Board of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH).
Aviral is a member of the Topics Editorial Board of the journal Cells, and he is associated with several journals in the field of Theranostics.
Professional memberships
- Treasurer and Executive Board Member, World Association of Radiopharmaceutical and Molecular Therapy
- Member, Therapy Center of Excellence of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Member, Center for Molecular Imaging Innovation and Translation of the SNMMI
- Member, European Neuroendocrine Tumor Society
- Member, European Society of Medical Oncology
Publications
- Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results. Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. J Nucl Med. 2021 Jun 24:jnumed.120.259192. doi: 10.2967/jnumed.120.259192. Online ahead of print.
- From Bench to Bedside-The Bad Berka Experience with First-in-Human Studies. Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. Semin Nucl Med. 2019 Sep;49(5):422-437. doi: 10.1053/j.semnuclmed.2019.06.002. Epub 2019 Jul 6.
- Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25.
- 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. J Nucl Med. 2018 May;59(5):809-814. doi: 10.2967/jnumed.117.193847. Epub 2017 Oct 12.
- First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study. Singh A, van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP. Cancer Biother Radiopharm. 2017 May;32(4):124-132. doi: 10.1089/cbr.2016.2173.
Click here for publications list.